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Abstract

 he oral microbiota is complex, multikingdom, interactive, and involves extensive biofilm formation.
T
While dominated by bacteria, Candida is a frequent member of this microbiota; however, several
other potentially pathogenic fungi (among around 100 identified species) appear to reside in some
individuals, including Cryptococcus, Aspergillus, and Fusarium. Oral candidiasis may manifest
as a variety of disease entities in normal hosts and in the immunocompromised. These include
pseudomembranous candidiasis (thrush), hyperplastic or atrophic (denture) candidiasis, linear
gingival erythema, median rhomboid glossitis, and angular cheilitis. The purpose of this review is
to describe the oral fungal microbiota (ie, oral mycobiota), common mouth diseases caused by its
members, predisposing factors and treatment, and the potential for causing disseminated disease
like their bacterial counterparts. (J Patient Cent Res Rev. 2019;6:252-261.)
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ILLUSTRATIVE CASE

A 40-year-old generally healthy, nondiabetic,
nonimmunocompromised man presented after having
awoken with a very bad taste in his mouth. He also had
noticed multiple white spots and some irritation on his
upper palate. He had very recently and simultaneously
been started on an inhaled steroid (triamcinolone
acetonide inhalation aerosol) and began using a
rubber over-the-counter mouth guard for treatment of
nocturnal bruxism. This mouth guard occluded much
of the upper palate and was noted to contain white
spots on the contacting surface. Importantly, symptoms
occurred despite rinsing his mouth following steroid
inhalation.
Physical examination was unremarkable except
for numerous small white plaques and some mild
erythema of his upper palate, with similar but lesser
lesions on his posterior tongue and oropharynx. Oral
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candidiasis (thrush) was diagnosed. The mouth guard
was discontinued, and he was treated with clotrimazole
troches. Signs and symptoms resolved over the next 2
days and did not recur.

INTRODUCTION

The microbiota of the human mouth is considered the
second most complex, after the colon, and exhibits
more diversity than the skin and other mucosal
sites.1-3 This oral microbiota is comprised of complex,
interactive communities of microorganisms and
nutrients, predominantly bacteria, on oral cavity
surfaces in biofilms.1,2,4-6 These intricate and interactive
biofilms may modulate the immune system and protect
involved species from environmental insults.4-6 Some
biofilm properties may actually improve or preserve
oral health and defend against potential invading
pathogens; others may increase virulence of potentially
harmful microorganisms and decrease the effects of
antimicrobial agents.5-7
Microbiota are affected by a number of local and
systemic factors, including heritable and other
individual factors, diet, general and oral health,
influx of new microorganisms (saliva exchanges with
Review

family members and other contacts, beginning in
infancy), teeth brushing, dentures, dental procedures
and appliances, mouthwashes, medications, and other
agents.1,4,6,8-11 Nearly 800 microbial species have been
identified in the oral cavity thus far.1,2,12,13 Most are
bacteria; however, fungi also are present, in addition to
archaea, protozoa, and bacteriophages.1-5,14,15

microorganisms of maternal origin), breastfeeding
versus formula feeding, perinatal antibiotics, and
other factors.10,16,20,21 Presumably, the healthiest infant
gastrointestinal, and by extension oral, microbiota
results from a combination of vaginal delivery,
breastfeeding, and lack of exposure to antibiotics and
other perinatal microbiota-modifying substances.21

Most disease caused by members of the oral microbiota
is bacterial. These mouth disorders — along with oral
tumors, recurrent aphthous stomatitis, and possibly
Behcet’s disease — may be associated with disturbances
of microbial biofilms/community members (dysbiosis)1
and “alterations of the homeostatic balance between
the host and resident microbes.”10 Local oral bacteriamediated diseases include dental caries (complex
interactions of acid producing oral bacteria and
fermentable carbohydrates), endodontic infections
(progression of dental caries resulting in invasion of
the pulp), gingivitis (reversible inflammatory disease
of the gums caused by bacterial plaque formation at
the gingival margin) and periodontitis (irreversible
destructive progression of gingivitis).1,4,6,10,16 The oral
cavity is the gateway to the gastrointestinal and lower
respiratory tracts.9,15 In addition, potentially invasive
microorganisms may enter the bloodstream from
the mouth via tissue breakdown from oral disease
or simply flossing one’s teeth.4 Bacterial microbiota
have been associated with a number of organ-specific
or generalized infections due to spread of potentially
pathogenic organisms from the oral cavity to the
particular sites.4 These include more classic infectious
entities such as aspiration pneumonia,17 abscesses, and
bloodstream infections.4 Additional reports suggest
possible etiologic roles of oral bacterial microbiota
in remote tumors, cardiovascular disease, diabetes,
rheumatoid arthritis and Alzheimer’s disease.1,5,17-19

The fungal genus studied most regarding colonization of
the infant gastrointestinal tract, including the mouth, is
Candida, a normal member of the vaginal mycobiota.20
C. albicans has been shown in vitro to influence the
bacterial makeup of early oral biofilms, specifically
favoring the presence of obligate anerobes.22 In a study
of 100 Swedish infants, oral colonization with Candida
species occurred in 12% of 4-week-old babies, and
levels remained stable at intervals up to 12 months.23
Infants with a furry pet at home had a lower frequency
of Candida at 3 months, and all but a single colonized
infant had older siblings at 12 months of age.23 Candidal
colonization increases with age.4

As oral bacteria have been well described, the purpose
of this review is to describe the fungal microbiota
(mycobiota) of the mouth, common mouth diseases
caused by its members, and the potential for causing
remote disease like their bacterial counterparts.

MEMBERS OF THE ORAL MYCOBIOME

Initial Colonization
Initial microbial colonization of the infant
gastrointestinal tract, including the mouth, differs
according to vaginal birth versus cesarean section (fewer
Review

In addition to Candida, several other species
including (presumably commensal) Saccharomyces,
Cryptococcus,
Aspergillus,
Malassezia,
and
Cladosporium have been demonstrated with molecular
techniques in fecal samples of very-low-birthweight
infants and children under 2 years of age.20 Little is
otherwise known regarding oral colonization by fungi
in children. In one study of Chinese children, 28 of
60 (46.7%) subjects 9 years old or younger had oral
yeasts recovered, including 15 Candida species, 7
unidentified yeasts, and 6 “other species,” while 13%
of 550 subjects 10–19 years old grew oral yeasts,
predominantly Candida.24
Culture-Based Studies
Approximately 100 fungal species have been identified
from the human mouth, most of them not cultivatable.5 In
a recent culture-based study of 40 healthy young student
adults from a single dental school in Portugal, 68% of
subjects harbored Candida species in their oral cavity.9
This study, which used kit-based manual identification
of yeasts and molecular diagnostics for molds, also
revealed that most subjects harbored Rhodotorula,
Penicillium, Aspergillus, and Cladosporium species
in their mouths. A minority of subjects harbored
Trichoderma, Scedosporium, Alternaria, and Rhizopus
fungal species in the oral cavity.9 The authors noted
www.aurora.org/jpcrr
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that the filamentous fungi (all listed species except
Candida and Rhodotorula) are mostly very common
environmental molds and frequently found in nasal
mucosa. They also documented intraindividual
stability but high interindividual variability over time.9
Recent culture-based studies of middle-aged and older
adults yield similar findings. Wang et al included all
age groups and used sequence information from the
internal transcribed spacer regions of the ribosomal
RNA gene cluster to identify yeasts recovered from the
oral cavity in 415 of 1799 (23.1%) community-dwelling
and hospitalized subjects tested.24 Of recovered yeasts,
298 of 415 (71.8%) were C. albicans, C. glabrata, C.
parapsilosis, or C. tropicalis species. Lesser recovered
species include Kodamaea ohmeri, other Candida
species, Trichosporon species, Cladosporium, Pichia,
Rhodotorula, S. cerevisiae, and rare other species such
as C. neoformans var. neoformans. This study found
that gender and ethnic background of subjects did not
contribute to the distribution of oral yeast species;
however, age, health status, birthplace, and current
geographic residence did.24 An additional culturebased study that used a variety of methods for species
identification studied 323 healthy adult volunteers
attending health maintenance examinations in Taiwan;
15% of subject oral cavities were colonized with yeast,
85% were Candida species.25 Other species included
2 strains of R. mucilaginosa and single strains of C.
albidus, P. ohmeri, Prototheca, Rhodotorula, Ustilago,
and S. cerevisiae.25
Molecular Studies
In a sentinel article, Ghannoum and colleagues,
using DNA analysis of oral-rinse specimens from 20
healthy individuals, identified 74 culturable and 11
nonculturable fungal genera (101 total species) in
healthy human mouths.12 Nearly half of these genera
were present in only 1 of the persons sampled; 15 genera
were present in 4 or more persons. Candida species
(8 of 16 were C. albicans) were identified in 75% of
persons and Cladosporium in 65%. Aureobasidium and
Saccharomyces-like species were each isolated from half
of those tested. Aspergillus and Fusarium species were
isolated in about one-third of specimens; Cryptococcus
species were identified in 20% of individuals.12 More
than 70% of identified genera are present in the
natural environment, including common domestic
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environments.12,26,27 A notable exception is C. albicans,
which does not generally survive in the environment.28
More recently, Mukherjee and colleagues used
pyrosequencing to compare the “core” mycobiome
(and bacteriome) in 12 HIV-infected patients to 12
matched subjects without HIV infection.29 C. albicans
was the most commonly identified fungal species in
both groups but was more frequently identified in
subjects with HIV (83% vs 58%). Overall, the most
common genera in those HIV-infected were Candida,
Epicoccum, and Alternaria, (92%, 33%, and 25%
prevalence, respectively, in tested subjects), whereas
Candida, Pichia, and Fusarium were most common in
control subjects (58%, 33%, and 33%, respectively).29
These authors also presented evidence that there
was an inverse relationship between core oral fungal
organisms described in their report as members of
the genus Pichia (Saccharomycetes yeasts whose
taxonomic classification is in fluxcf.30) and various
Candida species.29 Additional experiments indicated
that Pichia inhibits the growth of potential pathogens
Candida, Aspergillus, and Fusarium.29
Dupuy and colleagues investigated saliva samples
of 6 healthy human subjects utilizing revisions in
isolation technique and sequence-based taxonomy
assignments.13 Their results also demonstrated the
breadth and depth of fungal genera comprising the
oral mycobiota. There were several genera identified
that were not present in the study of Ghannoum et al,
most notably Malassezia, which was highly prevalent
and abundant. Potentially pathogenic genera present in
both studies include Candida, Aspergillus, Fusarium,
and Cryptococcus.12,13
Other reports pointed out the challenges of interpreting
data on the oral mycobiota based on molecular
approaches to identification of members.3,27 These
include specific technical issues; different taxonomic
nomenclature among particular databases; determining
at what frequency/density of identification constitutes
“membership;” the number of “normal” subjects
sampled; the potential for “tenacious” biofilms,
gingival sulci, and periodontal pockets to prevent
identification based on oral rinses; the number of
nonculturable fungal species; and the potential to
identify dead organisms.3,27
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DISEASE/INFECTIONS CAUSED BY
ORAL MYCOBIOTA

Dental Disease
Childhood dental caries, for example, may not be
strictly a bacterial disease. Streptococci associated
with Candida in oral biofilms may promote the
invasive properties of the latter.3,6,7 Falsetta and
colleagues presented evidence that C. albicans forms
a symbiotic relationship with Streptococcus mutans
such that the virulence of plaque biofilms is increased
in vitro and in vivo.31 In addition, a comparison of
children aged 6–12 years who did or did not have
a history of dental caries revealed a significantly
higher frequency of Candida species isolated from
intraoral swabs and concentrated oral rinses among
children with dental caries.32 Mixed infections of C.
albicans and Peptostreptococcus micros may result
in persistent endodontic infections.7
Oral Candidiasis
Among members of the oral mycobiota, Candida
species cause most infections of the oral mucosa,
typically in immunocompromised individuals and
presumably due to local overgrowth of the organisms.3
Xu and Dongari-Bagtzoglou noted that “the common
underlying link between all known host systemic
conditions associated with oral Candida overgrowth
is a functional immunodeficiency in the Th17 CD4+
cell subset.”3 Changing levels in oral bacterial
microbiota due to antibiotics may play an important
role in Candida overgrowth and infection; however,
the combination of antibiotics and local or systemic
immunosuppression may be a required setting for most
infections to germinate.3
In HIV-infected patients, the shift of C. albicans
from members of the oral microbiota to opportunistic
pathogen indeed appears to involve Th17 CD4+
functional depletion but also appears to involve
other mechanisms, including specific binding and
interactions between Candida and the HIV virus.33
Smoking is associated with increased Candida
carriage and pathogenicity, likely through a variety of
mechanisms.34 Also, a dysbiotic oral biota may result
in an exaggerated inflammatory response to fungal
opportunistic pathogens such as Candida.3 On the
plus side, the rate of salivary flow and certain salivary
proteins, along with other specific local responses,
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contribute to the innate resistance of oral mucosa to
C. albicans.35 Interestingly, as opposed to virulent
C. albicans, commensal Candida strains “induce
regulatory immune responses maintaining tissue
tolerance to the commensal fungi.”35
In addition to HIV infection, a variety of other
immunocompromising conditions and local factors
promote the oral pathogenesis of Candida species.
These include leukemia and other oncologic disease,
chemotherapy, radiation therapy, xerostomia, poor oral
hygiene, malnutrition, local or systemic corticosteroid
use, other immune modulating or xerogenic drugs,
antibiotics,
denture/retainer/mouth
guard
use
(especially if worn during sleep), diabetes mellitus,
Down syndrome, immunosenescence, and other
diseases of the mouth.28,35-41 Not commonly seen in the
general population (except in cases of multiple local
insults, such as described in our illustrative case), oral
candidiasis occurs in almost 20% of cancer patients,
9%–31% of AIDS patients, and 5%–7% of neonates.37
Fungal overgrowth typically results in accumulation
of hyphae (conversion from yeast form to hyphae is
critical for mucosal invasion) as well as keratin, fibrin,
necrotic tissue, and other products of epithelial cell
desquamation.35,36,38,39
Clinical Presentation and Diagnosis of Oral
Candidiasis: Oral candidiasis may take a variety
of clinical forms, which are divided into white or
erythematous (red) candidiasis.36,37,39 C. albicans is
isolated in association with oral candidiasis 70%–80%
of the time; however, other Candida species such as
C. glabrata and C. tropicalis are associated with a
minority of such infections.39
Pseudomembranous candidiasis (thrush) is the most
common form and typically involves generally
confluent white plaques on the hard and soft palate,
tongue (Figure 1), buccal mucosa, oropharynx,
or commonly, as seen in our illustrative case,
a combination of involved regions.28,36,38,39 A
distinguishing feature is the usual ability to easily
wipe off the white plaques, exposing an erythematous
surface.36-39 This entity may be acute or chronic. Patients
are usually asymptomatic, but affected individuals
may experience a sour taste, burning sensation, or
tendency to bleed at the involved sites.36,38
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Figure 1. Infant pseudomembranous candidiasis (thrush).

Figure 3. Acute atrophic (erythematous) candidiasis

Figure 2. Hyperplastic (white) oral candidiasis on the

Figure 4. Angular cheilitis.

The other form of white oral candidiasis, the
hyperplastic form, presents as “well-circumscribed,
slightly elevated, white plaques most commonly
adherent to the buccal mucosa,” perhaps with
involvement of the labial commissures or adjacent
parts of the mouth (Figure 2).36,38 Lesions may be
nodular or speckled in appearance and range from
translucent to opaque. The manifestations of this
type of candidiasis cannot be easily wiped off as
with pseudomembranous candidiasis. Hyperplastic
candidiasis may mimic leukoplakia and has potential
for malignant change.36,38,39

There are several forms of erythematous oral
candidiasis.36 Acute atrophic candidiasis particularly
occurs in HIV-infected patients and manifests as
erythematous patches, most often on the palate (Figure
3). Other areas of the mouth may be involved, and
atrophy of the lingular papillae may occur. Typical
symptoms include a burning sensation in the mouth
(especially with spicy foods) and/or soreness of the
tongue and lip.28,36,38 In addition to the predisposing
conditions noted, iron or vitamin B12 deficiency has
been linked with this entity, which may occur following
use of broad-spectrum antibiotics.36

labia, adjacent buccal mucosa and tongue. (Photograph
from Williams D, Lewis M. Pathogenesis and treatment
of oral candidosis. J Oral Microbiol. 2011;3(1):5771,
republished with permission from David Williams and
Michael Lewis per Creative Commons license.)
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on the palate of an adult. (Photograph from Williams D,
Lewis M. Pathogenesis and treatment of oral candidosis.
J Oral Microbiol. 2011;3(1):5771, republished with
permission from David Williams and Michael Lewis per
Creative Commons license.)
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Chronic atrophic candidiasis primarily occurs in poorly
fitting denture wearers and results from Candida
overgrowth (sometimes in association with bacteria)11
due to inhibited salivary flow — the relatively acidic
and anaerobic microenvironment produced by the
dentures — and the potential for continuous inoculation
with the fungi and bacteria.36,38,39 Lesions are generally
only in areas contacting the dentures and are generally
red and swollen. This entity may be asymptomatic or
result in a lateral burning sensation in the mouth.36
Angular cheilitis, also known as perlèche, may occur
with denture-related candidiasis or individuals who
frequently lick their lips or traumatize the corners of
their mouths.36,38,39 Individuals with redundant skin or
wrinkles at the angle of the mouth may be predisposed
to candidal overgrowth, and various B vitamin or iron
deficiencies have been associated. Signs are usually
bilateral, with red, fissured patches associated with
pain or soreness observed along the commissures of
the mouth (Figure 4).36,38,39 The anterior nostril region
also may be affected.39 Staphylococcus aureus is often
involved, along with Candida.36,38,39
Similarly, bacteria and Candida may be involved
in the development of another erythematous oral
manifestation, linear gingival erythema, which
presents as a discrete red band along the gingival
margin of one or more teeth. This entity may occur in
progressive HIV disease; however, it can also develop
in healthy children.36
In the final form of erythematous oral candidiasis,
median rhomboid glossitis (central papillary atrophy),
the association with chronic Candida infection may not
be completely causative.39 It is quite rare and appears as a
generally asymptomatic, smooth, and glossy rhomboidshaped red patch or plaque in the center of the dorsal
tongue (may involve a developmental abnormality),
anterior to the circumvallate papillae. It is associated
with smoking and inhaled corticosteroids.36,38,39
Chronic mucocutaneous candidiasis is an additional
variant of oral candidiasis. It is a less well-defined
disorder, consisting of several of the aforementioned
forms of candidiasis in association with chronic skin
and nail lesions that are generally unresponsive to
topical therapy. It may begin in childhood, involve
single-gene mutations, and is typically associated with
Review

abnormalities of the endocrine system.15,28,36 Significant
disfigurement and social rejection may result from the
clinical manifestations.28 Smokers may present with a
chronic multifocal candidiasis without other obvious
risk factors.36 Cheilocandidiasis is an ulcerating lip
lesion, typically on the lower vermilion border.36
Whether Candida species are related to noninfectious
oral disease requires further investigation. Recently,
virulence factors of Candida species isolated from the
mouth of patients with oral squamous cell carcinoma
were more pronounced than from species isolated
from mouths of patients with lichen planus, chronic
candidiasis, and asymptomatic carriers of Candida.42
Diagnosis of these previously described oral Candida
disorders is made by typical history and appearance
and may be confirmed by fungal wet mount or
stained smear, culture, or biopsy.36,38,39 The differential
diagnosis is rather broad, with white lesions needing to
be distinguished from simply the presence of milk or
other white food, other oral fungal disease, local trauma
or burns, leukoplakia, nutritional deficiency, chronic
immunobullous diseases, lichen planus, mucositis
of chemotherapy, and primary syphilis. In addition
to trauma, geographic tongue, pernicious anemia,
zinc deficiency, and lichen planus, erythematous oral
candidiasis is to be distinguished from systemic lupus
erythematous and erythema multiforme.36-38 Diagnosis
is usually made clinically; however, fungal smear or
culture, and possibly oral biopsy, may be required.36,38,39
Follow-up of chronic hyperplastic candidiasis, including
serial biopsy as necessary, is important to rule out
leukoplakia and to monitor for dysplastic features.39
Treatment and Prevention of Oral Candidiasis:
Treatment of oral candidiasis should be based on
type of manifestation, immune status of the host, and
degree of involvement or lack of response to previous
therapy.36 The breadth of treatment options and details
are well covered in the article by Millsop and Fazel,
to which the reader is referred.36 Commonly used
treatments are listed in Table 1.
In all cases, good oral and denture hygiene and
removal of the underlying predisposing factor(s),
when possible, are very important. This includes daily
flossing and twice daily brushing of teeth and tongue,
regular dental care, treatment of xerostomia with
www.aurora.org/jpcrr
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Table 1. Common Treatment of Oral Candidiasis36-39
Disease

Treatment

Alternative

Most common side effects

Infant thrush

Nystatin oral suspension
(100,000 U/mL), 1 mL into
each cheek 4 times a day
until 2 days past resolution

Oral fluconazole (in age 6
months or older) 6 mg/kg on
day 1, followed by 3 mg/kg
daily × at least 14 days

Nystatin: minimal; skin irritation

Nystatin oral suspension
(100,000 U/mL), 4–6 mL hold
and swallow 4 times a day
until 2 days past resolution
(at least 7–14 days if HIV)

Non-HIV: oral fluconazole as
above; HIV: oral fluconazole
3–6 mg/kg daily × 7–14 days

Nystatin: as above

or

Clotrimazole: nausea/vomiting

Nystatin, as above

Clotrimazole, as above

Nystatin*: as above

or

Clotrimazole*: as above

Oral fluconazole 200 mg on
day 1, then 100–200 mg daily
× 7–14 days

Fluconazole*: as above

Childhood thrush

Adult oral candidiasis,
most forms

Angular cheilitis

In age 3 years or older:
clotrimazole 10 mg lozenge
dissolved slowly 5 times a
day × 14 days

Nystatin with or without
triamcinolone applied 2
times a day × 14 days

Fluconazole: nausea/vomiting

Fluconazole: nausea/vomiting,
headache

Skin irritation

*Pregnancy category C.

frequent water and/or ice chips or sugarless lozenge
intake, control of diabetes, and limitation of topical
or systemic corticosteroid and antibiotic use when
possible.36 Dentures may be soaked for 30 minutes
twice weekly, preferably daily, with white vinegar,
chlorhexidine gluconate 2% suspension, or a solution
of 1 part household bleach mixed with 10 parts water,
followed by thorough rinse and air drying.36,39 Mouth
guards should be well ventilated when stored, not
shared, and washed with warm, soapy water after use.41
For infant thrush, the mainstay of treatment remains
nystatin oral suspension (100,000 U/mL), 1 mL into
each cheek 4 times a day until 2 days past resolution.
Oral fluconazole is an alternative for those 6 months old
or older: 6 mg/kg on day 1, followed by 3 mg/kg daily
for at least 14 days. Infant pacifiers and bottle nipples
should be boiled; in breastfed babies, the mothers
areolae may be treated with topical antifungals such
as nystatin for the duration of treatment of the infant.37
For oropharyngeal candidiasis prophylaxis, oral
fluconazole or itraconazole are more effective
than placebo in people receiving chemotherapy or
258 JPCRR • Volume 6, Issue 4 • Fall 2019

radiation for cancer, and daily or weekly fluconazole
or itraconazole prophylaxis is effective in persons
with HIV infection.43 Topical clotrimazole lozenges
and miconazole slow-release tablets, or single-dose
(750 mg) fluconazole, may be as effective as standard
oral agents for symptom reduction in those with
HIV.43 Fluconazole may be used prophylactically in
immunocompromised infants and children.43
When treating oral candidiasis in pregnant women,
prescribers should take into account the pregnancy risk
categories of available medications.
Other Oral Fungal Infections
Other invasive fungal organisms that have been
identified as potential members of the oral mycobiota
may cause oral disease, if rarely. C. neoformans
may produce oral lesions in the form of superficial
ulcerations, nodules, or granulomas. These lesions
may mimic oral carcinoma.39 Aspergillus species
may cause palatal or other oral disease, which often
appear as black or yellow necrotic lesions following
progression from infection in the maxillary sinuses.39
Similarly, saprophytic Mucoraceae has been cultured
Review

from healthy oral cavities and may cause necrosis
or ulceration of the palate in immunocompromised
individuals via extension from paranasal infection.39
Geotrichum is an uncommon oral mycobiota member
and has been reported to cause oral disease in
immunocompromised patients or diabetics.44

extent than other nonsterile sites.49,50 Implications are
unclear, however, this fungus illustrates the importance
of good antifungal stewardship (even in treatment of
minor oral disease), not only to reduce cost and toxicity
but to reduce pressure on emergence of resistance.51

IMPORTANCE OF ORAL MYCOBIOTA
BEYOND THE MOUTH

The oral mycobiome is complex, interactive, and
involves extensive biofilm formation. Candida is a
microorganism frequently colonized in the human
mouth, and several other pathogenic fungi appear
to be oral residents in some individuals. Protean oral
disease is commonly caused or co-caused by Candida
species and, rarely, by other fungi. Prevention is largely
dependent on maintaining good oral hygiene and
avoiding unnecessary corticosteroids and antibiotics.
Clinical treatments range from oral suspensions or
lozenges to oral tablets. As Hager and Ghannoum
recently emphasized,45 while much is known about the
potential for oral bacteria to ultimately infect or affect
other areas of the body, much remains to be investigated
regarding the importance of oral fungi such as Candida
or Cryptococcus as agents of more disseminated disease.

Xu and Dongari-Bagtzoglou hypothesized that
pathogenic fungi such as Cryptococcus, Aspergillus,
and Fusarium, if indeed common residents of the
oral cavity, may normally be “under continuous
surveillance and control by healthy immune systems.”3
Ghannoum and colleagues agreed and questioned
whether harboring potential fungal pathogens in the
oral cavity could predispose a susceptible host to an
opportunistic infection elsewhere.12 Microaspiration
of microbiome organisms from the upper airway
is likely the chief source of microorganisms in the
healthy lung; however, the composition of organisms
differs from that seen in oral wash specimens.27
Known interactions between C. albicans and
streptococci also may promote synergistic colonization
in the gastrointestinal tract.3 Oral candidiasis may
spread beyond the mouth to cause esophageal or
gastric candidiasis.37 There is evidence in HIV-infected
patients that mycobiome profiles in the respiratory and
gastrointestinal tracts are similar to that in the mouth.45,46
Whether or not there are meaningful associations with
fungi such as Candida, or Saccharomyces, on such
things as Crohn’s disease remains to be confirmed, let
alone whether or not the source of these fungi is the oral
cavity.27 In addition, there is evidence, at least for gut
Candida, that these species can influence immunity at
other areas of the body.15 Candida has been postulated
to potentially promote tumor formation via its properties
of adhesion, biofilm production, and protease and
hemolytic activity, in addition to being detected in
samples of adenomas (with unclear associations).47
Additionally, as an example, a recent association
(directionality unknown) has been made between oral
Candida residence and colony counts and psoriasis.48
Finally, in consideration of recent press articles, Candida
auris, an emerging, often multidrug-resistant, invasive,
difficult-to-identify pathogen, can apparently colonize
the oropharynx and mouth, although to a much lesser
Review

CONCLUSIONS

Patient-Friendly Recap
• Although more well known for harboring
bacteria, the normal human mouth also
contains many fungal microorganisms, some
of which can cause infection.
• The most common fungal disease of the
mouth is called “thrush.” It occurs in infants,
children, and adults and is usually treated with
oral suspensions, lozenges, or tablets.
• The best approach to preventing oral fungal
disease is to consistently maintain oral
hygiene, especially if using dentures or mouth
guards, and avoiding unnecessary steroid
medications and antibiotics.

Conflicts of Interest
None.
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